Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma
S Jagannath, CC Jackson, JM Schecter… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting CAR-T therapy, is
approved in the United States and Europe for patients with relapsed/refractory multiple …
approved in the United States and Europe for patients with relapsed/refractory multiple …
Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed/refractory …
PURPOSE Although chimeric antigen receptor T therapy (CAR-T) cells are an established
therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models …
therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models …
[HTML][HTML] Current Novel Targeted Therapeutic Strategies in Multiple Myeloma
Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of
immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites …
immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites …
[HTML][HTML] ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen …
H Hashmi, A Kumar, MA Kharfan-Dabaja… - … and Cellular Therapy, 2024 - Elsevier
Chimeric antigen receptor T cell therapy (CAR-T) has revolutionized the management of
relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is …
relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is …
[HTML][HTML] Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium …
Idecabtagene vicleucel (ide-cel) has shown impressive efficacy in relapsed/refractory
multiple myeloma (RRMM). This study aimed to investigate the impact of absolute …
multiple myeloma (RRMM). This study aimed to investigate the impact of absolute …
[HTML][HTML] CAR-T Therapy in Multiple Myeloma: Looking Beyond
G Maiorana, G Antolino, G La Verde, A Tafuri - Hemato, 2024 - mdpi.com
Multiple Myeloma is a hematological neoplasm that, over the recent few years, has benefited
from numerous therapeutic options. Among the latter, CAR-T stands out as the most recent …
from numerous therapeutic options. Among the latter, CAR-T stands out as the most recent …
Improving Access to T-cell Therapies in Multiple Myeloma
BA Derman - Clinical Lymphoma Myeloma and Leukemia, 2024 - Elsevier
The introduction of chimeric antigen receptor (CAR) T-cell therapies and bispecific
antibodies (BsAb) into the treatment armamentarium for relapsed/refractory multiple …
antibodies (BsAb) into the treatment armamentarium for relapsed/refractory multiple …